DLL3 and neuroendocrine carcinoma: However, strong DLL3 expression was predominantly observed in GEP-NEC, while GEP-NET G3 generally displayed lower DLL3 expression intensity, with only one case showing strong expression (1/15 strongly DLL3-positive GEP-NET G3 vs. 34/133 strongly DLL3-positive GEP-NEC; p = 0.003).